445263-72-9

Basic information

• Product Name: (6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-morpholin-4-yl-phenyl)-amine
• Synonyms: (6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-morpholin-4-yl-phenyl)-amine;GS-9973 intermediate;6-Bromo-N-[4-(4-morpholinyl)phenyl]imidazo[1,2-a]pyrazin-8-amine;6-bromo-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine
• CAS NO: 445263-72-9
• Molecular Formula: C₁₆H₁₆BrN₅O
• Molecular Weight: 374.23514
• Mol File: 445263-72-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-morpholin-4-yl-phenyl)-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-morpholin-4-yl-phenyl)-amine(445263-72-9)
• EPA Substance Registry System: (6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-morpholin-4-yl-phenyl)-amine(445263-72-9)

Safety Data

• Hazardous Substances Data: 445263-72-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-morpholin-4-yl-phenyl)-amine is used as a compound in pharmaceutical research for the development of new drugs and therapies. Its unique structure may offer novel interactions with biological targets, potentially leading to the creation of innovative treatments for various diseases and conditions.
Used in Chemical and Biochemical Studies:
In the field of chemical and biochemical research, (6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-morpholin-4-yl-phenyl)-amine is used as a subject of study to better understand its properties and potential effects. This knowledge can be crucial for identifying its possible applications and optimizing its use in various industries, including pharmaceuticals, materials science, and environmental science.

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 10389-51-2 1-morpholino-4-nitrobenzene 
• 2524-67-6 4-morpholino-4-yl-phenylamine 
• 63744-22-9 6,8-dibromoimidazo[1,2-a]pyrazine 

Downstream Products

• 445263-57-0 C₂₁H₂₀N₆O 
• 1229208-44-9 6-(1H-indazol-6-yl)-N-[4-(4-morpholinyl)phenyl]imidazo[1,2-a]pyrazin-8-amine 

Relevant articles and documents

2, 6, 8 - Polysubstituted imidazo [1, 2 - a] pyrazine and synthesis method and application thereof

The invention discloses I, 2 and 6 polysubstituted imidazo [8 - 1] pyrazine of formula (2 - a) or a pharmaceutically acceptable salt thereof. The invention also discloses application of the 2, 6 and 8 - polysubstituted imidazo [1, 2 - a] pyrazine or pharmaceutically acceptable salts thereof as TYK2 inhibitors in preparation of drugs for preventing and treating tumor or inflammation diseases. The invention also provides a synthetic method of the 2, 6, 8 - polysubstituted imidazo [1, 2 - a] pyrazine or a pharmaceutically acceptable salt thereof.

Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor

As the aim to discover orally SYK inhibitors for solid tumor treatment, a series of novel derivatives based on imidazo[1,2-a]pyrazine scaffold were designed, synthesized and evaluated. Structure-activity relationship study of both enzymatic and cellular assays led to the identification of compound 12f. The novel SYK inhibitor 12f showed potent antitumor activity against solid tumors with favorable drug-like properties of lipophilicity and solubility. 12f could induce cell apoptosis of ovarian and lung cancer cell lines. In SKOV3 xenograft mouse model, oral administration of 12f led to significant tumour regression without obvious toxicity. 12f improved the limited response of traditional SYK inhibitors in solid tumors in vitro and in vivo. Taken together, this compound may act as a promising lead compound for further development of new SYK inhibitors for solid tumor therapy.

HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR

A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof. Specifically, the present invention relates to a compound of formula (I), the compound having dual inhibitory activity for Syk and/or Syk-HDAC.

Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells

Co-crystallisation of the imidazo[1,2-a]pyrazine derivative 15 (3-chloro-N-(4-morpholinophenyl)-6-(pyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine) with Aurora-A provided an insight into the interactions of this class of compound with Aurora kinases. This led to the design and synthesis of potent Aurora-A inhibitors demonstrating up to 70-fold selectivity in cell-based Aurora kinase pharmacodynamic biomarker assays.